15,117 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Acquired by Legato Capital Management LLC

Legato Capital Management LLC bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 15,117 shares of the medical equipment provider's stock, valued at approximately $1,214,000.

A number of other institutional investors have also bought and sold shares of the company. Silverberg Bernstein Capital Management LLC increased its stake in shares of Lantheus by 0.4% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider's stock valued at $1,834,000 after acquiring an additional 100 shares in the last quarter. Moody National Bank Trust Division increased its stake in Lantheus by 1.1% in the second quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider's stock valued at $1,203,000 after purchasing an additional 162 shares in the last quarter. Shaker Investments LLC OH raised its holdings in shares of Lantheus by 0.7% during the first quarter. Shaker Investments LLC OH now owns 27,962 shares of the medical equipment provider's stock valued at $1,740,000 after purchasing an additional 182 shares during the period. NBC Securities Inc. boosted its position in shares of Lantheus by 28.4% during the 1st quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider's stock worth $53,000 after purchasing an additional 191 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of Lantheus by 184.1% in the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock valued at $26,000 after buying an additional 208 shares during the period. Institutional investors own 99.06% of the company's stock.

Insider Buying and Selling

In other Lantheus news, Director Gerard Ber sold 15,500 shares of the business's stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the transaction, the director now directly owns 21,221 shares in the company, valued at $2,047,402.08. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Lantheus news, President Paul Blanchfield sold 2,000 shares of the business's stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the sale, the president now owns 98,980 shares of the company's stock, valued at approximately $9,540,682.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gerard Ber sold 15,500 shares of the firm's stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now directly owns 21,221 shares of the company's stock, valued at $2,047,402.08. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 54,066 shares of company stock worth $4,977,240. Insiders own 1.50% of the company's stock.

Lantheus Stock Up 1.7 %

NASDAQ:LNTH traded up $1.84 on Tuesday, hitting $109.15. The stock had a trading volume of 553,207 shares, compared to its average volume of 1,053,181. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The firm's fifty day simple moving average is $97.98 and its two-hundred day simple moving average is $78.47. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.55 and a current ratio of 4.68. The stock has a market cap of $7.57 billion, a P/E ratio of 16.60 and a beta of 0.51.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). The business had revenue of $394.10 million for the quarter, compared to analysts' expectations of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business's revenue was up 22.5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.40 earnings per share. Analysts predict that Lantheus Holdings, Inc. will post 6.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on LNTH shares. StockNews.com downgraded Lantheus from a "buy" rating to a "hold" rating in a research note on Friday, May 3rd. Leerink Partners increased their target price on Lantheus from $106.00 to $127.00 and gave the stock an "outperform" rating in a report on Thursday, July 11th. B. Riley boosted their price target on shares of Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a research note on Thursday, July 25th. Truist Financial dropped their price objective on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating on the stock in a research note on Thursday, August 1st. Finally, Mizuho boosted their target price on shares of Lantheus from $90.00 to $100.00 and gave the stock a "buy" rating in a research report on Friday, May 3rd. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, Lantheus presently has an average rating of "Moderate Buy" and an average target price of $119.00.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.